Over $49 billion worth of debt service pressure and liquidity risk continues to rise in 2026 for the HRU.

In the south-west region, the annual financing plan announcement issued on 11 March 2026 by the well-established Medicines Enterprise Remedial Unit, revealed that the proposed financing for 2026 amounted to RMB 20,490 million and that the subsidiaries intended to finance 28,910 billion yuan, totalling RMB 49.4 billion. At the same time, the reagent stock of the controlled stock proposed to be added to the registered medium-term instruments does not exceed RMB 2 billion and to cover more than RMB 5 billion. However, as a result of the ongoing debt collection, corporate debt pressure was high, with short-term borrowing of RMB 18,496 million in circulation, netting of the total of 31 provinces in 2026 million yuan in urban areas in the country.